Zevra Therapeutics, Inc. · NASDAQ:ZVRA

Zevra Therapeutics — Kempharm — Corporate Update (October 2018)

8 slides from Zevra Therapeutics's corporate update, Oct 30, 2018

  1. Slide 1: APADAZ License Agreement with KVK Tech, Inc.

    K Pharm APADAZ® License Agreement with KVK Tech, Inc.

  2. Slide 2: Cautionary Note Regarding Presentation Information

    Cautionary Note Regarding Presentation Information This presentation contains forward-looking statements, including statements about our plans to develop and commercialize our product candidates, anticipated milestone and royalty payments, planned collaboration activities with our strategic partners

  3. Slide 3: APADAZ License Agreement Call Participants

    APADAZ® License Agreement Call Participants + Travis Mickle, Ph.D. — President & Chief Executive Officer + R. LaDuane Clifton, CPA — Chief Financial Officer, Secretary & Treasurer * Gordon K. “Rusty” Johnson — Chief Business Officer MUR tt

  4. Slide 4: License Agreement

    APADAZ® License Agreement v KemPharmenters into a definitive license agreement with KVK Tech, Inc. for the commercialization of APADAZ KVK Tech is granted the exclusive right for all commercial, manufacturing, packaging and distribution activities for APADAZ in the U.S. and will be responsible for r

  5. Slide 5: KVK Tech, Inc.

    KVK Tech, Inc. v KVK Tech is one of the largest controlled substance manufacturers and distributors in the U.S. Private company founded in 2004 + 12,000 square foot, state-of-the art controlled substance vault is one of the largest in the U.S.; capable of handing CI through CV products Current overa

  6. Slide 6: Commercialization Strategy

    APADAZ® Commercialization Strategy KVK is expected to continue the same strategy for commercializing APADAZ; approach not expected to require the establishment of a large field sales force Non jonal PBM and MCO Partners + Pre and post-launch activities include outreach and plan adoption by pharmacy

  7. Slide 7: KemPharm's Next Steps

    KemPharm’s Next Steps Accelerate preparation for anticipated 2H 2019 APADAZ® commercial launch o Begin technology transfer to KVK including transfer of NDA o KVK to initiate validation batches in preparation of commercial launch © Support KVK to initiate regional pilot launches as early as 2H 2019 +

  8. Slide 8: Pharm

    K Pharm APADAZ® License Agreement with KVK Tech, Inc.

Kempharm — Corporate Update (October 2018) on 6ix